Includes bibliographical references and index.
|Statement||edited by Nicholas B. La Thangue and Lasantha R. Bandara.|
|Series||Cancer drug discovery and development|
|Contributions||La Thangue, Nicholas B., Bandara, Lasantha R.|
|LC Classifications||RC268.42 .T37 2002|
|The Physical Object|
|Pagination||xii, 352 p. :|
|Number of Pages||352|
|LC Control Number||2001051561|
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of ed cancer therapies are sometimes called "molecularly targeted drugs," "molecularly targeted therapies," "precision medicines," or similar names. In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists provide, in an easy-to-understand format, a detailed account of these latest research developments and spell out their implications for cancer drug discovery and clinical. Targeted therapy is sometimes called precision medicine or personalized medicine. This is because they are made to exactly target specific changes or substances in cancer cells, and these targets can be different even when people have the same type of cancer. Certain types of tumors are tested for different targets after a biopsy or surgery. Targeted therapy does have some drawbacks. These include: Cancer cells can become resistant to targeted therapy. For this reason, they may work best when used with other types of targeted therapy or with other cancer treatments, such as chemotherapy and radiation. Drugs for some targets are hard to develop.
This book covers a wide range of novel biochemical targets that appear to be the best leads in terms of designing novel targets for anticancer drug design. New Molecular Targets for Cancer Chemotherapy is a unique, multi-disciplinary effort, with internationally respected authors from the . This book provides basic, translational, and clinical cancer researchers with an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. Novel Cancer Drugs Target Tumor Roots. Avastin was the first of the new kind of cancer therapies that work by cutting off the blood to a tumor from the growth of new blood vessels -- a process Author: Salynn Boyles. In December , the PARP inhibitor Alaparib was approved for women with BRCA mutations who have experienced a recurrence of ovarian cancer. Bevacizumab (Avastin), a targeted therapy that has been studied frequently in ovarian cancer, and targets the blood vessels that supply the tumor and aid in growth.
Chemotherapy is the prevailing method for treatment of cancer but is often associated with side effects and development of multidrug resistance (MDR). MDR is the major impediment to successful eradication of cancer as it allows the cancer cells to survive against cytotoxic effect of structurally and functionally unrelated drugs and radiations. Concepts, Mechanisms, and New Targets for Chemotherapy. by. Cancer Treatment and Research (Book 78) Thanks for Sharing! You submitted the following rating and review. We'll publish them on our site once we've reviewed : Springer US. DOI: /EdBook_AM American Society of Clinical Oncology Educational Book - published online before print Janu PMID: A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Cited by: 1. In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists explain in detail the therapeutically-relevant protein targets that contribute to cancer pathology and spell out their implications for cancer drug discovery and clinical application.